1.09

0.93% 0.01

After Hours: 1.10 0.01 +0.92%

Shattuck Labs Inc (STTK)

Overview News Price History Option Chain Financials Discussions Forecast

Shattuck Labs Inc stock is traded at $1.09, with a volume of 103.31K. It is up +0.93% in the last 24 hours and down -16.79% over the past month. Shattuck Labs Inc is a clinical-stage biotechnology company pioneering the development of dual-sided fusion proteins as an entirely new class of biologic medicine. Its product candidate, SL-172154, has been rationally designed to simultaneously inhibit the CD47/SIRPa checkpoint interaction to restore an anti-tumor immune response and to activate the CD40 costimulatory receptor to bolster an immune response. Its product candidate, SL-279252, which is being developed in collaboration with Takeda Pharmaceuticals, or Takeda, has been rationally designed to simultaneously inhibit the PD-1/PD-L1 interaction and activate the OX40 receptor.

Previous Close:

$1.08

Open:

$1.06

24h Volume:

103.31K

Relative Volume:

0.18

Market Cap:

$51.56M

Revenue:

$2.72M

Net Income/Loss:

$-85.08M

P/E Ratio:

-0.5023

EPS:

-2.17

Net Cash Flow:

$-70.93M

1W Performance:

-1.80%

1M Performance:

-16.79%

6M Performance:

-85.45%

1Y Performance:

-52.61%

1-Day Range:

$1.05

$1.10

1-Week Range:

$0.94

$1.14

52-Week Range:

$0.94

$11.76

Shattuck Labs Inc Stock (STTK) Company Profile

Name

Shattuck Labs Inc

Sector

Healthcare (1200)

Industry

Biotechnology (682)

Phone

512-900-4690

Address

500 W. 5TH STREET, AUSTIN

Employee

Twitter

Next Earnings Date

2024-11-07

Latest SEC Filings

STTK's Discussions on Twitter

Compare STTK with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
STTK Shattuck Labs Inc	1.09	51.56M	2.72M	-85.08M	-70.93M	-2.17
VRTX Vertex Pharmaceuticals Inc	464.56	119.70B	10.63B	-479.80M	-1.35B	13.33
REGN Regeneron Pharmaceuticals Inc	754.87	82.75B	13.85B	4.65B	3.32B	35.06
ARGX Argen X Se Adr	614.59	36.73B	1.86B	-40.29M	-1.28B	-4.16
ALNY Alnylam Pharmaceuticals Inc	253.74	32.53B	2.09B	-332.26M	16.06M	-4.14
BNTX Biontech Se Adr	120.72	28.50B	3.30B	-501.07M	1.03B	11.54

Shattuck Labs Inc Stock (STTK) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Oct-02-24	Downgrade	Citigroup	Buy → Neutral
Oct-02-24	Downgrade	Needham	Buy → Hold
Oct-01-24	Downgrade	H.C. Wainwright	Buy → Neutral
Jun-17-24	Downgrade	BTIG Research	Buy → Neutral
Aug-31-22	Initiated	BTIG Research	Buy
Jun-01-22	Initiated	Citigroup	Buy
May-02-22	Initiated	H.C. Wainwright	Buy
Apr-14-21	Initiated	Berenberg	Buy
Jan-11-21	Initiated	Evercore ISI	Outperform
Nov-03-20	Initiated	Citigroup	Buy
Nov-03-20	Initiated	Cowen	Outperform
Nov-03-20	Initiated	Needham	Buy

View All

Shattuck Labs Inc Stock (STTK) Latest News

Nov 26, 2024

GSA Capital Partners LLP Invests $121,000 in Shattuck Labs, Inc. (NASDAQ:STTK) - Defense World

Nov 26, 2024

Nov 25, 2024

Shattuck Labs Announces Participation in Upcoming December Conferences - EIN News

Nov 25, 2024

Nov 24, 2024

Shattuck Labs Falls To US$1.01, But Insiders Sold At Lower Price - Simply Wall St

Nov 24, 2024

Nov 22, 2024

Shattuck Labs stock plunges to 52-week low at $1.06 By Investing.com - Investing.com Canada

Nov 22, 2024

Nov 21, 2024

Shattuck Labs stock plunges to 52-week low at $1.06 - Investing.com India

Nov 21, 2024

Nov 20, 2024

Citigroup Downgrades Shattuck Labs (STTK) - MSN

Nov 20, 2024

Nov 19, 2024

Shattuck Labs’ (STTK) Neutral Rating Reaffirmed at HC Wainwright - Defense World

Nov 19, 2024

Nov 18, 2024

STTK (Shattuck Labs) Degree of Operating Leverage : -0.01 (As of Jun. 2024) - GuruFocus.com

Nov 15, 2024

Shattuck Labs' (STTK) "Neutral" Rating Reiterated at HC Wainwright - MarketBeat

Nov 15, 2024

Shattuck Labs sees cash runway into 2027 - Yahoo Finance

Nov 15, 2024

Nov 14, 2024